Genoscience’s molecular modeling capabilities will be coupled with RFS Pharma’s drug development expertise.
RFS Pharma and Genoscience Pharma formed a drug discovery joint venture to develop protease inhibitors for the treatment of life-threatening viral infections.
The companies will collaborate on the discovery, optimization, and development of lead compounds into therapeutic agents. Genoscience’s molecular modeling capabilities will be coupled with RFS Pharma’s expertise in pharmacology and drug development.
“This strategic alliance expands the breath of our company beyond our expertise in nucleoside analogs,” explains Raymond F. Schinazi, founder and executive director of RFS Pharma. “Genoscience also provides RFS Pharma with a presence in Europe for further expansion.”